Morning Briefing — Thursday, April 23, 2026

Published 07:00 ET · Informational only, not investment advice

Tape at a glance

What happened overnight

Two macro catalysts broke a weeks-long uncertainty overhang and sent risk assets surging on Wednesday. First, President Trump stated he has "no intention" of firing Fed Chair Jerome Powell, reversing threatening rhetoric that had been injecting Fed-independence risk premium into every asset class. Second, Trump said the 145% tariffs on China "will come down substantially — but not to zero," with Treasury Secretary Bessent confirming preliminary contact with Chinese counterparts and signaling de-escalation within "weeks." Wednesday's cash session closed: S&P 500 +2.51% to 5,287; Nasdaq +2.74% to 16,300; Dow +2.66% (+1,016 pts) to 39,187 — first close above 5,200 on the S&P since April 7. Overnight futures are adding to those gains on the Alphabet (+6.7%) and Snap (+18%) post-close earnings beats. The critical caveat: China's Ministry of Commerce denied formal trade talks are underway, meaning this rally is partly priced on unconfirmed de-escalation — a denial or escalation from Beijing would cut these gains quickly.

Today's calendar

• Pre-market — Philip Morris (PM), Danaher (DHR), American Airlines (AAL), Kimberly-Clark (KMB), Dow Inc (DOW), Saia (SAIA) — all reported; results mixed (PM/DHR beat, AAL guide cut, DOW miss)
• No tier-1 US macro releases today (no CPI, NFP, FOMC, PCE, or GDP) — tape is entirely earnings and headline-driven
• After close tonight — Tesla (TSLA), ServiceNow (NOW), Chipotle (CMG), Stryker (SYK) — TSLA is the binary event; consensus EPS $0.42 / $20.1B revenue; whisper numbers below consensus
• Fed: No scheduled FOMC speakers today; Fed in "wait and see" mode; next decision May 6-7; ~8% probability of May cut; first full cut priced September 2026

Top 10 trade ideas, ranked by conviction

1. SNAP — Long

• Asset class: Equity
• Catalyst: Q1 2026 earnings beat reported April 22 AC: revenue $1.36B (+14% YoY, +2.3% vs consensus), Adj. EPS $0.08 vs $0.01 est. (+700%), DAU 460M (+9% YoY), Adj. EBITDA $108M vs $69M est. — across-the-board blowout.
• Setup: +18.1% pre-market to ~$9.98 on 67M shares (vs. avg volume ~20-25M). This is a genuine fundamental reset, not a momentum blip — the advertising model is working and user growth re-accelerated. No Q2 guidance issued (macro uncertainty), which removes a ceiling on near-term price discovery.
• Entry: $9.80–$10.20 (let the first 15-min opening candle form; buy the first constructive pullback)
• Stop: $9.20 (below the pre-market gap-fill zone; if it gaps up and immediately reverses with volume, exit)
• Target: $11.50–$12.00 (prior resistance cluster; ~20% from entry)
• Reasoning: SNAP was pricing in near-zero profitability; the $108M EBITDA print vs $69M consensus is not a rounding error — it's a structural shift signal. Digital ad budgets held firm despite tariff uncertainty, echoing GOOGL and PINS. The no-guidance call removes a known risk (bad Q2 guide), and with the stock still in single digits, the float is wide enough for institutional adds. The 67M share pre-market volume suggests real conviction from smart money, not just retail.
• Risk: No Q2 guidance creates a "relief rally with no follow-through" risk. If broader markets sell off intraday on China denial headlines, high-beta names like SNAP get hit hardest. Position size accordingly.
• Conviction: High
• Levels note: Entry/stop/target are indicative, derived from headline sources at time of writing. Verify against a live chart before executing.

2. GOOGL — Long

• Asset class: Equity
• Catalyst: Q1 2026 EPS $2.81 vs $2.63 est. (+$0.18 beat), revenue $90.23B vs $88.67B est. (+$1.56B beat), Google Cloud +28% YoY, raised dividend and authorized new buyback.
• Setup: +6.7% pre-market to $166.28 on 12.4M shares. This is a $2T company gapping 6.7% on 12M pre-market shares — that's real institutional repositioning. Cloud revenue at +28% growth is the crux: it dispels the narrative that AI capex is eating margins without revenue upside.
• Entry: $163.50–$167.00 (let price settle; buy on first dip from open, or on a flag formation in the first hour)
• Stop: $158.00 (below the pre-market gap fill; a full reversal below this level would invalidate the earnings-driven thesis)
• Target: $178–$182 (prior technical cluster and ~10% upside from entry)
• Reasoning: GOOGL was being priced as a company under siege — AI commoditizing search, antitrust overhang, ad recession fears. The Q1 print invalidates each of those narratives simultaneously: search held, Cloud accelerated to +28%, margins expanded. The buyback announcement adds mechanical bid. This isn't just a gap day; it's a re-rating event that takes multiple sessions to digest. Institutions that were underweight will be adding into pullbacks all week.
• Risk: DOJ antitrust case continues in background. Any headline on forced browser/search remedies would cap the rally. Also: the broader "China trade optimism might be fake" risk applies to all mega-cap tech.
• Conviction: High
• Levels note: Entry/stop/target are indicative, derived from headline sources at time of writing. Verify against a live chart before executing.

3. TSLA — Short (options: buying puts or put spreads)

• Asset class: Options / Equity
• Catalyst: Tesla reports Q1 2026 earnings after close today. Consensus EPS $0.42, revenue $20.1B; whisper numbers are below consensus. Shares already -6.05% pre-market to $231.20 on 26.1M shares — the market is pre-pricing disappointment before the number.
• Setup: The stock is down on massive pre-market volume as the street positions for a miss. Q1 deliveries were already reported and were weak; price cuts have compressed margins; Elon Musk's DOGE distractions have generated negative brand sentiment and boycotts in key European markets. The put/call ratio on TSLA is skewed negative.
• Entry: Short shares at $230–$235 open; or buy May $220 puts at market open. This is an earnings-event trade — size appropriately for binary risk.
• Stop: $245 (if TSLA reverses sharply and rallies through $245 on massive buying, the "bad expectations already priced" thesis kicks in and the short is wrong)
• Target: $210–$215 on a miss + bad guidance; $195–$200 if delivery miss + margin guide down + Musk says nothing reassuring on call
• Reasoning: At $231 pre-market, TSLA still commands a premium valuation ($230 / ~$0.42 EPS = ~550x trailing EPS) that requires a strong growth narrative to sustain. The growth narrative is impaired: Q1 deliveries were the weakest in years, competition from BYD and Chinese EVs intensified, and Musk's public persona has become a liability in markets that matter (Europe). The 26M pre-market shares is the market front-running the miss. Even a "line" quarter with no downside guidance leaves TSLA with no catalyst to rally tonight, and any weakness will compound the pre-existing -6% move.
• Risk: TSLA surprises with strong margins or Musk makes an FSD/robotaxi announcement that re-ignites growth narrative. Also: short squeezes in TSLA are historically violent. Use defined-risk structures (puts) rather than naked short if possible.
• Conviction: High
• Levels note: Entry/stop/target are indicative, derived from headline sources at time of writing. Verify against a live chart before executing.

4. BTC — Long

• Asset class: Crypto
• Catalyst: Trump/Powell clarity (Fed independence restored) + US-China trade de-escalation signals + Bitcoin ETF inflows resuming (estimated +$300–500M today) triggered a break above $90K resistance. BTC now at $93,700.
• Setup: BTC broke above $90K (former resistance, now support) and the 200-day MA (~$88K) with authority. The Fear & Greed Index flipped from Fear to Greed. RSI at ~65 — momentum is strong but not yet overbought. Volume confirms the move.
• Entry: $91,500–$93,000 on any intraday pullback; or break above $94,000 for momentum entry
• Stop: $88,500 (below 200-DMA; a close below $88K invalidates the breakout thesis)
• Target: $95,000 (near-term resistance) → $100,000 (psychological major level)
• Reasoning: The two catalysts driving this move are durable over a multi-session timeframe: (1) Fed independence restored removes a tail risk that had been suppressing institutional appetite for risk assets including BTC; (2) US-China de-escalation optimism, even if partially overstated, reduces the macro-risk premium on crypto. ETF inflows snapping a multi-week outflow streak is the most actionable confirmation signal — that's institutional money coming in, not retail FOMO. $95K is the next logical target; $100K is the destination if trade-deal headlines firm up.
• Risk: China denies formal talks, sending a risk-off shock. BTC correlates to macro risk-off sharply. Also: if TSLA or another major after-hours miss triggers a broad equities selloff overnight, BTC often follows.
• Conviction: High
• Levels note: Entry/stop/target are indicative, derived from headline sources at time of writing. Verify against a live chart before executing.

5. SMH — Long (VanEck Semiconductor ETF)

• Asset class: Equity (ETF)
• Catalyst: US-China trade de-escalation is directly bullish for semiconductors — the sector most exposed to the tariff war via supply chains (TSMC, NVIDIA's China sales, AMD's data center customers). SMH +2.8% pre-market with NVDA +3.1%, AMD +2.9%, AVGO +2.7%.
• Setup: SMH has been the most tariff-whipsawed ETF in the market — it dropped 35%+ from January highs on escalation fears. A sustained de-escalation narrative (even if unconfirmed) creates violent mean-reversion trades in SMH. TXN's weak guide (-7.2%) is a minor headwind to SMH but is an industrial/embedded chip story, not a data-center/AI chip story which dominates SMH weighting.
• Entry: $215–$220 at open (let the gap fill slightly, or enter the breakout above Wednesday's close)
• Stop: $208 (below the pre-market gap; if the broader trade optimism narrative cracks, SMH will sell off hard)
• Target: $235–$242 (prior resistance zone from mid-March; ~10% upside)
• Reasoning: The trade between "145% tariffs" and any number below 100% is worth 15–20% in SMH — the sector was pricing in permanent decoupling. Any credible de-escalation path triggers a re-rating that has far more room to run than the +2.8% pre-market move suggests. The GOOGL Cloud +28% growth confirms hyperscaler capex is intact, which is the primary demand signal for NVIDIA and AMD. The NVDA/AMD/AVGO weights alone are ~40% of SMH — one more positive AI/cloud data point could add another leg.
• Risk: China officially denies formal talks (headline risk). TXN's weak embedded/industrial guide suggests the non-AI chip recovery is still fragile. Don't hold SMH through a China denial headline.
• Conviction: High
• Levels note: Entry/stop/target are indicative, derived from headline sources at time of writing. Verify against a live chart before executing.

6. ETH — Long

• Asset class: Crypto
• Catalyst: ETH +8.9% in 24 hours, outperforming BTC (+3.8%) on a combination of: macro risk-on (same BTC catalyst), Pectra upgrade anticipation, ETH ETF inflow resumption, and ETH/BTC ratio recovering off multi-year lows.
• Setup: ETH broke above $1,750 resistance (now support); next targets $1,800 (psychological) → $2,000 (major structural). The ETH/BTC ratio recovery is a differentiated catalyst — when ETH outperforms BTC after a prolonged underperformance period, the rotation often runs for days not hours.
• Entry: $1,740–$1,770 on pullback, or on a break above $1,800 for momentum
• Stop: $1,680 (below the broken resistance level; failure here means the breakout is false)
• Target: $1,850 (near-term) → $2,000 (major)
• Reasoning: ETH had a unique double-catalyst on top of the macro tailwind: the Pectra upgrade is a concrete protocol improvement with a known timeline (development milestone), creating genuine fundamental demand, not just macro reflexivity. The ETH ETF market is much less mature than BTC's and has more room for inflows to move price. The ETH/BTC ratio bounce is the signal that underweight ETH positions are being rebuilt after a period of relative underperformance — that rotation carries momentum.
• Risk: BTC consolidates below $90K pulling the whole market down. Pectra upgrade delay. ETH has more correlation to risk-off than BTC in recent months.
• Conviction: Medium-High
• Levels note: Entry/stop/target are indicative, derived from headline sources at time of writing. Verify against a live chart before executing.

7. PINS — Long

• Asset class: Equity
• Catalyst: Pinterest Q1 2026 beat: Revenue $1.05B vs $1.01B est., EPS $0.40 vs $0.35 est., MAU 570M (+10% YoY). Pre-market +10.7% to $27.52 on 14.9M shares.
• Setup: PINS has been in a prolonged downtrend, so this beat + double-digit gap creates a "re-rating off a low base" dynamic. The 570M MAU at +10% growth is the key number — it shows the platform is still growing users globally. Revenue per MAU is still well below Meta/Snap levels, meaning there's monetization runway ahead.
• Entry: $26.80–$27.80 (first pullback from gap; avoid chasing the open print)
• Stop: $25.50 (below the gap; if PINS fades more than 50% of the gap by midday, the bull thesis for the day is impaired)
• Target: $30.00–$31.00 (~10% from entry; prior resistance zone)
• Reasoning: The digital ad ecosystem had a strong Q1 universally (SNAP, GOOGL, now PINS), which validates that advertisers did not pull back budgets meaningfully despite macro noise. PINS is the most under-owned of the big ad platforms relative to its user growth, and a 10% MAU growth quarter resets the conversation. At $27, PINS is still far below its 52-week highs — there's room to run as index rebalancing and growth-fund re-entry follows earnings-beat confirmation.
• Risk: The gap has already moved 10.7%; this is an extended entry. If the broad market reverses on China-denial headlines, high-beta ad-tech catches a double hit. Size smaller than GOOGL/SNAP.
• Conviction: Medium
• Levels note: Entry/stop/target are indicative, derived from headline sources at time of writing. Verify against a live chart before executing.

8. DXCM — Short

• Asset class: Equity
• Catalyst: DexCom Q1 2026 miss: EPS $0.32 vs $0.41 est. (-22%), revenue $1.04B vs $1.10B est., FY2026 guidance cut to $4.30–$4.45B from $4.60–$4.75B (midpoint -$300M). Pre-market -15.83% to $65.12 on 7.2M shares.
• Setup: Guidance cuts of this magnitude in medical devices typically take 3–5 sessions to fully re-price, because institutional holders must update models, get research notes written, and decide whether to trim. The initial day-one gap is usually followed by at least one more leg lower on reduced guidance revisions or sell-side downgrades. XLV is dragging as a whole, reducing the sector headwind of any mean-reversion.
• Entry: Short on the first bounce after open, ideally $67–$69 range (expect some initial overshooting then a dead-cat bounce)
• Stop: $72 (if DXCM bounces more than 15% from the lows, the guidance cut is being discounted as temporary; cover)
• Target: $58–$60 (the fundamental re-rating to the new guidance range; ~10–12% below entry)
• Reasoning: A $300M midpoint guidance cut on a company with $4.5B revenue is a 6–7% top-line miss versus prior expectations — material enough to force model revisions across the street. The reason cited (slower international adoption) is not a one-quarter story; it's a structural slowdown signal in GLP-1 adjacent markets. The XLV sector drag adds a technical headwind. DXCM is still at a significant premium to healthcare earnings multiples even at $65, meaning the re-rating has room to run.
• Risk: Short squeeze in a name already down 15.8% is possible if any positive catalyst emerges (FDA approval, partnership announcement). Position size is key. Also: a broad market reversal upward would compress the short opportunity window.
• Conviction: Medium
• Levels note: Entry/stop/target are indicative, derived from headline sources at time of writing. Verify against a live chart before executing.

9. USD/JPY — Short (long JPY)

• Asset class: FX / Futures
• Catalyst: DXY is at 99.10 and structurally weak: (1) Fed independence fears unwound but dollar still impaired by trade uncertainty; (2) 10Y real yields fell when trade-optimism narrative reduces tariff-inflation premium; (3) BOJ has been flagging willingness to continue rate normalization. USD/JPY currently at 142.18.
• Setup: USD/JPY traded between 141.60–142.80 today. The DXY recovery from below 98 to 99.10 is a partial bounce, not a reversal — the conditions that drove the dollar lower (tariff uncertainty, Fed credibility questions) have not fully resolved. Yen tends to be bought on global macro uncertainty; any China denial headline would spike it. The trade is: long JPY (short USD/JPY) with tight stops.
• Entry: Short at 142.50–142.80 (on any USD bounce intraday)
• Stop: 143.80 (if USD/JPY breaks decisively above 143.80, the dollar is recovering more than expected)
• Target: 140.00–140.50 (prior support / psychological level)
• Reasoning: The dollar's structural problem is unresolved: even with Powell safe, the uncertainty around tariff-driven inflation makes the Fed's path opaque. BOJ normalization is directionally towards higher JPY rates. If China denies trade talks today or tomorrow, the resulting risk-off would spike JPY sharply. The risk/reward on this trade — risking ~130 pips to make ~200 pips — is asymmetric, and the entry near the top of the day's range is clean.
• Risk: US-China trade deal details emerge rapidly, sending DXY back above 100 and USD/JPY to 144+. BOJ meeting surprises with dovish language. A strong TSLA print tonight that sparks risk-on would also hurt.
• Conviction: Medium
• Levels note: Entry/stop/target are indicative, derived from headline sources at time of writing. Verify against a live chart before executing.

10. HIMS — Long

• Asset class: Equity
• Catalyst: Reports suggest the FDA has upheld access to compounded GLP-1 drugs for patients unable to access branded versions — a significant positive for Hims & Hers' compounding pharmacy business. Pre-market +11.35% to $28.35 on 9.9M shares.
• Setup: HIMS has been in a regulatory limbo on GLP-1 compounding access for months; any FDA clarity that preserves the revenue stream (compounded semaglutide, tirzepatide) is a positive surprise. The 11.35% move on 9.9M shares is meaningful given the name's average daily volume.
• Entry: $27.00–$28.50 (let the open volatility settle; look for a 15-min base before entering)
• Stop: $25.50 (below the gap; if the FDA news is walked back or mischaracterized, the thesis evaporates)
• Target: $32.00–$33.00 (~15% from entry; prior resistance from Jan/Feb)
• Reasoning: HIMS' entire bull narrative hinges on whether the FDA allows compounding pharmacies to fill GLP-1 prescriptions when branded supply is constrained. If today's news confirms that access remains, the market was dramatically underpricing this revenue stream. At $28, HIMS is still 50%+ below its 52-week high despite a growing GLP-1 business. The regulatory catalyst is genuine and time-specific, which is the type of edge that generates multi-day follow-through.
• Risk: The FDA ruling may be nuanced, conditional, or misreported in pre-market. If the actual text of the FDA action is more limited than headlines suggest, the stock reverses sharply. This is a watch-the-open name — confirm the news before adding size.
• Conviction: Watch-only until open confirms catalyst; then Medium
• Levels note: Entry/stop/target are indicative, derived from headline sources at time of writing. Verify against a live chart before executing.

What I'm watching but not trading

• RTX (+4.76%): Q1 beat + FY guide raise ($6.00–6.15 EPS) is clean. Not trading because it's already +4.76% pre-market and defense names often gap-and-chill. Adding to the watchlist for a day-two entry if it pulls back to the $133–134 range.
• TXN (-7.2%): The Q2 guide ($3.74–4.06B vs $4.27B consensus) is a 5–6% revenue shortfall — not a short here because the stock is already gapping 7.2% down and semiconductor names with trade-optimism tailwinds can see buy-the-dip buyers absorb the selling. Watching for a short entry if the bounce stalls near $172–175.
• AAL (-guide): American Airlines cut FY guidance citing macro uncertainty and softening corporate travel. An interesting macro signal about consumer and corporate spending resilience, but too much event risk (TSLA tonight + China headlines) to initiate a trade. Monitoring for sector read on XTN/JETS.
• ENPH (+10.15%): Enphase's Q1 beat + Q2 guide above consensus is a genuine solar recovery signal. Not in the top 10 because of the sector's policy sensitivity — any IRA rollback news (possible given political climate) could crush solar names regardless of fundamentals. Watch if $65 holds as new support.

Footer

This briefing is generated by an automated research agent using publicly available information. It is not investment advice, does not constitute a recommendation to buy or sell any security, and should not be relied upon for trading decisions without independent verification. Day trading carries substantial risk of loss. Past catalysts do not predict future price action. Do your own research.